Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
BioMarin Pharmaceutical |
---|---|
Information provided by: | BioMarin Pharmaceutical |
ClinicalTrials.gov Identifier: | NCT00299000 |
The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.
Condition | Intervention | Phase |
---|---|---|
Mucopolysaccharidosis VI Maroteaux-Lamy Syndrome |
Drug: galsulfase |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 4 Multi-Center, Multi-National, Open-Label, Randomized, Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With Maroteaux-Lamy Syndrome (MPS VI) |
Estimated Enrollment: | 4 |
The primary objective of the study is to evaluate the efficacy of two dose levels of Naglazyme in preventing the progression of skeletal dysplasia in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.
The secondary objective of the study is to evaluate the efficacy of the two dose levels of Naglazyme in preventing several measures of disease progression in infants under the age of one year who have MPS VI by monitoring urinary GAGs, gross and fine motor function, cardiac function, vision, hearing, and use of health resources.
The safety objective of the study is to evaluate the safety of two dose levels of Naglazyme in infants under the age of one year who have MPS VI.
Ages Eligible for Study: | up to 1 Year |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Linda A Scott, RN, BA | 415-506-6700 | lscott@bmrn.com |
United States, California | |
Children's Hospital Oakland | Recruiting |
Oakland, California, United States, 94609 |
Study Director: | Celeste Decker, MD | BioMarin Pharmaceutical |
Study ID Numbers: | ASB-008 |
Study First Received: | March 2, 2006 |
Last Updated: | September 10, 2007 |
ClinicalTrials.gov Identifier: | NCT00299000 |
Health Authority: | United States: Food and Drug Administration |
Metabolism, Inborn Errors Mucopolysaccharidoses Metabolic Diseases Genetic Diseases, Inborn Lysosomal Storage Diseases |
Connective Tissue Diseases Mucopolysaccharidosis type 6 Mucopolysaccharidosis Metabolic disorder Mucopolysaccharidosis VI |
Pathologic Processes Disease Syndrome Mucinoses Carbohydrate Metabolism, Inborn Errors |